ANTENGENE-B (06996) announced that on March 3, 2026, its wholly-owned subsidiaries, Antengene Biologics Limited and Antengene (Hangzhou) Biotechnology Co., Ltd. (collectively, the "Licensor"), entered into a licensing agreement with UCB (the "Licensee"). Under the agreement, the Licensor grants the Licensee an exclusive global license for the further development, manufacturing, and commercialization of ATG-201, along with the use of related production technologies.

In return, the Licensor will receive an upfront and near-term milestone payment of $80 million, which includes a $60 million upfront payment and an additional $20 million near-term milestone payment contingent upon meeting certain conditions. Furthermore, the Licensor is eligible to receive up to approximately $1.1 billion in future milestone payments based on successful development and commercialization, as well as tiered royalties on future net sales.

ATG-201 is an investigational CD19/CD3 bispecific T-cell engager (TCE) specifically designed and developed for the treatment of B-cell-mediated autoimmune diseases. The Licensor plans to submit clinical trial applications for ATG-201 in China and Australia in the first quarter of 2026. Following the completion of the first-in-human (Phase 1) clinical studies in these two regions, subsequent clinical and related development work for ATG-201 will be transferred to the Licensee.

The Licensee's shares are listed on Euronext Brussels (Stock Code: UCB). Founded in 1928, the Licensee is a global biopharmaceutical company focused on discovering and developing innovative medicines and solutions to transform the lives of patients with severe diseases of the immune system or central nervous system. The Licensee employs over 9,000 people in approximately 40 countries worldwide and reported revenue of €7.7 billion in 2025.